TherapeuticsMD (TXMD) Change in Accured Expenses (2010 - 2026)
TherapeuticsMD (TXMD) posted Change in Accured Expenses of $434000.0 for Q1 2026, up 283.12% on a QoQ basis from -$237000.0 in Q4 2025, and up 58.39% year-over-year from $274000.0 in Q1 2025.
TherapeuticsMD (TXMD) Change in Accured Expenses (2010 - 2026) Analysis & Trends
TherapeuticsMD's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $434000.0 for Q1 2026.
- Quarterly Change in Accured Expenses rose 58.39% year-over-year to $434000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $432000.0 (up 235.42% YoY) and the FY2025 annual result came in at $272000.0, up 127.04% from the prior year.
- Change in Accured Expenses was $434000.0 for Q1 2026 at TherapeuticsMD, up from -$237000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $19.1 million in Q3 2022 and bottomed at -$14.1 million in Q4 2022.
- A 5-year average of -$691235.3 and a median of -$237000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 3282.27% — and 2025, when it sank 331.82%.
- TherapeuticsMD's Change in Accured Expenses stood at -$14.1 million in 2022, then soared by 73.04% to -$3.8 million in 2023, then soared by 81.79% to -$691000.0 in 2024, then jumped by 65.7% to -$237000.0 in 2025, then soared by 283.12% to $434000.0 in 2026.
- Business Quant data shows TXMD's Change in Accured Expenses at $434000.0 in Q1 2026, -$237000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 434,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 434,000.00 |
| Mar 31, 2026 | 434,000.00 |
| Dec 31, 2025 | -237,000.00 |
| Dec 31, 2025 | -237,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | -190,000.00 |
| Jun 30, 2025 | -190,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | -691,000.00 |
| Dec 31, 2024 | -691,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | -413,000.00 |
| Mar 31, 2024 | -413,000.00 |
| Dec 31, 2023 | -3.80 Mn |
| Dec 31, 2023 | -3.80 Mn |